Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of Orantinib, an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor, and fibroblast growth factor receptor, in patients with advanced hepatocellular carcinoma (HCC).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.
• Treatments: Orantinib

Criteria

Inclusion Criteria:

• Age 20-74

• PS 0-2

• Patients who did not respond to surgery, RFA, TAE, chemotherapy, or radiotherapy

• Chid-Pugh A or B

• At least one measurable lesion by RECIST criteria

Exclusion Criteria:

• Large amount of pleural effusion or ascites

• Esophageal varices

• Simultaneously active double cancer